SFRP5: Adipokine Secreted Frizzled-Related Protein 5 Acting as a Wnt5a Decoy Receptor with Anti-Inflammatory and Metabolic-Protective Functions in Research

# SFRP5: Adipokine Secreted Frizzled-Related Protein 5 Acting as a Wnt5a Decoy Receptor with Anti-Inflammatory and Metabolic-Protective Functions in Research

Introduction

The Wnt signaling superfamily, best known for regulating embryonic development, stem cell maintenance, and cancer, has increasingly been recognized as a modulator of adult metabolic homeostasis. Within this family, the non-canonical Wnt5a/JNK pathway has emerged as a pro-inflammatory, insulin-resistance-promoting axis in metabolic tissues. The adipokine SFRP5 (Secreted Frizzled-Related Protein 5) functions as a natural endogenous brake on this pathway — a soluble decoy receptor that sequesters Wnt5a and prevents it from engaging signaling-competent Frizzled receptors.

In obesity, SFRP5 production by white adipose tissue (WAT) is markedly reduced, while Wnt5a expression in metabolic tissues and macrophages is elevated. This imbalance — insufficient SFRP5 to neutralize excess Wnt5a — contributes to chronic low-grade adipose inflammation, macrophage infiltration, and systemic insulin resistance. Conversely, recombinant SFRP5 administration in obese mouse models attenuates adipose inflammation and improves glucose homeostasis, establishing SFRP5 as a therapeutically relevant adipokine.

SFRP5 occupies a unique niche: it is one of the few characterized adipokines whose mechanism involves direct neutralization of a morphogen/cytokine (Wnt5a) rather than signaling through a receptor of its own. This makes its biology conceptually aligned with other decoy receptor systems (e.g., IL-1Ra, TRAIL-R3/R4) while acting on the Wnt pathway.

Discovery and Classification

The SFRP Protein Family

The secreted frizzled-related proteins (SFRPs) are a family of five secreted glycoproteins (SFRP1-5) that all share a cysteine-rich domain (CRD) homologous to the extracellular Wnt-binding domain of Frizzled receptors. By presenting this Frizzled-like CRD in soluble form, SFRPs compete with membrane-bound Frizzled receptors for Wnt ligand binding — effectively acting as Wnt decoys or antagonists.

SFRPs also contain a netrin-related motif (NTR) domain that contributes to dimerization and heparin-binding, influencing their extracellular localization and diffusion range.

While SFRP1-4 have established roles in Wnt pathway modulation during development and in various cancers, SFRP5 gained attention specifically as an adipose-enriched secreted protein with metabolic regulatory functions.

Identification as an Adipokine

Ohman et al. (2003) identified SFRP5 as one of the most highly expressed transcripts in murine white adipose tissue through expression profiling. Subsequent work by Mori et al. (2012) in Science (PMID 22923435) established SFRP5 as a bona fide adipokine with direct anti-inflammatory and metabolic-protective functions, defining its Wnt5a-neutralizing mechanism and its dysregulation in obesity — the foundational paper in the field.

Gene Structure and Protein Biochemistry

The SFRP5 gene (chromosome 10q24.1) spans ~14 kb with four exons encoding a 346-amino-acid precursor protein including a 21-aa signal peptide.

Mature SFRP5 protein (~38 kDa, glycosylated to ~40-42 kDa) contains:

• •N-terminal cysteine-rich domain (CRD, aa 1-120): 10 conserved cysteines forming 5 disulfide bonds; homologous to Frizzled receptor extracellular domains; directly contacts Wnt proteins
• •Linker region (~30 aa): flexible hinge between domains
• •C-terminal netrin-related motif (NTR domain, aa 151-300): contributes to protein stability, dimerization, and heparan sulfate proteoglycan interactions; contains 6 conserved cysteines

SFRP5 can form homodimers through NTR domain interactions, potentially increasing avidity for Wnt ligands. N-glycosylation at multiple sites (predicted N85, N232, and others) contributes to secretion efficiency and extracellular stability.

Wnt5a selectivity: While most SFRPs can bind multiple Wnt ligands, SFRP5 shows preferential binding to Wnt5a (a non-canonical Wnt) and Wnt3a (a canonical Wnt) in binding studies. In metabolic contexts, the Wnt5a-neutralizing activity appears dominant, as Wnt5a drives the JNK/inflammatory pathway implicated in insulin resistance.

SFRP5 Expression and Tissue Distribution

Primary source: White adipose tissue (WAT)

SFRP5 is most highly expressed in mature white adipocytes within WAT. Expression is significantly lower in:

• •Stromal-vascular fraction (preadipocytes, macrophages, endothelial cells) than in mature adipocyte fraction
• •Brown adipose tissue (BAT)
• •Liver, skeletal muscle, heart — low to undetectable
• •Brain — expressed in specific neuronal populations
• •Retinal pigment epithelium — developmental expression
• •Pancreatic ductal cells — limited expression

Regulation of SFRP5 expression:

Suppressed by:

• •Obesity / high-fat diet: SFRP5 mRNA and serum levels fall 50-70% in obese mice and humans
• •TNF-α: directly suppresses SFRP5 transcription in adipocytes; creates a positive feedback loop (low SFRP5 → more Wnt5a/JNK inflammation → more TNF-α → less SFRP5)
• •Hypoxia: adipose hypoxia in obese WAT suppresses adipokine expression broadly
• •Free fatty acids (palmitate, oleate): reduce SFRP5 mRNA in differentiated adipocytes

Induced by:

• •Thiazolidinediones (TZDs/PPARγ agonists): rosiglitazone, pioglitazone → PPARγ activation → SFRP5 transcription (PPRE in SFRP5 promoter region supports this)
• •Adipocyte differentiation: SFRP5 rises dramatically during 3T3-L1 preadipocyte differentiation to mature adipocytes
• •Exercise: some evidence for exercise-induced SFRP5 elevation in WAT

Wnt5a: The Primary Target Cytokine

Wnt5a Biology

Wnt5a is a prototypical non-canonical Wnt ligand that primarily signals through non-β-catenin pathways:

Wnt5a/Ror2 → JNK pathway: Wnt5a binds Frizzled receptors (especially Fz2, Fz5) in complex with Ror2 co-receptor → activates Dishevelled → c-Jun N-terminal kinase (JNK) phosphorylation → AP-1 transcription → pro-inflammatory cytokine production (TNF-α, IL-6, IL-1β, MCP-1)

Wnt5a/Frizzled → RhoA/ROCK pathway: Activates Rho GTPases → cytoskeletal remodeling; involved in macrophage polarization and migration

Wnt5a inhibition of canonical Wnt/β-catenin: In some contexts, Wnt5a can antagonize β-catenin signaling, promoting LRP6 degradation — relevant to adipocyte and osteoblast fate decisions.

Wnt5a in Metabolic Inflammation

Wnt5a is elevated in:

• •Obese adipose tissue macrophages (crown-like structures)
• •Circulating monocytes of obese individuals
• •Atherosclerotic plaques
• •Liver in non-alcoholic steatohepatitis (NASH)
• •Skeletal muscle of insulin-resistant subjects

Wnt5a from macrophages signals in paracrine to adipocytes → JNK activation → IRS-1 Ser307 phosphorylation → insulin receptor signaling blockade → local insulin resistance. Macrophage-derived Wnt5a also promotes its own M1 polarization in an autocrine loop.

SFRP5 Mechanism of Action: Wnt5a Neutralization

Direct Binding and Sequestration

SFRP5 binds Wnt5a through its CRD domain with sufficient affinity to compete with membrane Frizzled receptors. By sequestering Wnt5a in the extracellular space, SFRP5 prevents Wnt5a from engaging cell surface Ror2/Frizzled complexes and activating downstream JNK signaling.

This is directly analogous to how IL-1Ra (interleukin-1 receptor antagonist) blocks IL-1 signaling, or how soluble TNF receptors (etanercept precursor concept) neutralize TNF-α — a decoy receptor mechanism.

Downstream Effects of SFRP5/Wnt5a Neutralization

When SFRP5 successfully sequesters Wnt5a:

1. Reduced JNK phosphorylation in macrophages and adipocytes

2. Reduced AP-1-driven inflammatory gene expression: TNF-α, IL-6, MCP-1, IL-1β

3. Preserved IRS-1 Tyr phosphorylation: less Ser307 inhibitory phosphorylation → maintained insulin receptor signal transduction

4. Reduced macrophage infiltration into WAT: less MCP-1 → less monocyte recruitment → fewer crown-like structures

5. Maintained adiponectin expression: inflammation suppresses adiponectin; SFRP5 preserves adipokine balance

Key Study: Mori et al. (2012) Science

The founding paper by Mori et al. (2012, Science, 336(6079), 348-351, PMID 22923435) established SFRP5 as a metabolically important adipokine through several complementary approaches:

Adipose SFRP5 expression in obesity:

• •SFRP5 mRNA was 3-4 fold lower in epididymal WAT of diet-induced obese (DIO) C57BL/6 mice vs. lean controls
• •Serum SFRP5 protein was correspondingly reduced in obese mice
• •Obese human subjects had lower serum SFRP5 than BMI-matched non-obese controls

Sfrp5−/− mice on high-fat diet:

• •Developed more severe glucose intolerance, insulin resistance, and adipose inflammation than wild-type DIO controls
• •Greater macrophage infiltration (crown-like structures) in WAT
• •More JNK phosphorylation in WAT and liver
• •Not different from WT under normal chow — phenotype requires metabolic stress

SFRP5 gain-of-function (adenoviral overexpression) in DIO mice:

• •Improved glucose tolerance and insulin sensitivity without changing body weight
• •Reduced adipose inflammation (fewer crown-like structures, lower MCP-1/IL-6)
• •Decreased JNK phosphorylation in WAT

Wnt5a-specific mechanism:

• •Wnt5a neutralization with anti-Wnt5a antibody phenocopied SFRP5 overexpression
• •SFRP5-mediated protection was abolished in Wnt5a-deficient contexts
• •JNK inhibitor SP600125 also ameliorated the Sfrp5−/− phenotype, confirming the Wnt5a → JNK pathway as the operative mechanism

Human Serum SFRP5 Studies

Multiple clinical studies have measured serum SFRP5 as a metabolic biomarker:

Consistently observed associations:

• •Serum SFRP5 inversely correlates with BMI, waist circumference, and body fat percentage
• •Lower serum SFRP5 in type 2 diabetes, metabolic syndrome, and polycystic ovary syndrome (PCOS)
• •Inverse association with HOMA-IR (insulin resistance index)
• •Positive correlation with adiponectin levels (both are WAT-derived "beneficial" adipokines)
• •Inverse correlation with CRP, IL-6 (inflammatory markers)
• •Lower SFRP5 in non-alcoholic fatty liver disease (NAFLD), correlating with disease severity

Cardiovascular associations:

• •Lower serum SFRP5 in coronary artery disease patients
• •Some studies associate low SFRP5 with increased carotid intima-media thickness (CIMT)
• •Atherosclerotic plaques express elevated Wnt5a — SFRP5 deficiency may unmask vascular Wnt5a inflammation

Effect of interventions:

• •Weight loss (bariatric surgery, lifestyle) → SFRP5 increases in WAT and/or serum
• •TZD therapy → SFRP5 increases
• •Exercise training → some studies show SFRP5 elevation

Limitations: Most human studies are cross-sectional and observational; causality cannot be inferred. Serum SFRP5 assay standardization across studies remains a challenge.

SFRP5 in Adipogenesis

Beyond its anti-inflammatory function, SFRP5 participates in adipocyte differentiation by modulating canonical Wnt signaling:

Canonical Wnt/β-catenin is anti-adipogenic: Active β-catenin signaling maintains preadipocytes in an undifferentiated state by suppressing C/EBPα and PPARγ. This is why adipogenic differentiation protocols must suppress Wnt — β-catenin must be downregulated for adipogenesis to proceed.

SFRP5 in differentiation context: SFRP5 expression rises sharply during adipocyte differentiation (3T3-L1 model). While it primarily targets Wnt5a (non-canonical), it may also partially neutralize canonical Wnt ligands in the adipose microenvironment, facilitating PPARγ activation and differentiation progression.

This creates an interesting developmental logic: as preadipocytes differentiate into adipocytes, SFRP5 is upregulated to sequester Wnt5a and protect mature adipocytes from inflammatory signals — SFRP5 as both a product of and a protector of adipogenesis.

Comparisons with Other Anti-Inflammatory Adipokines

SFRP5 is distinctive in using a decoy mechanism rather than conventional receptor-mediated signaling, making it both conceptually unique among adipokines and potentially easier to replace with exogenous protein supplementation.

Research Tools and Models

Current Research Frontiers

SFRP5 in NASH/NAFLD

Given SFRP5's hepatoprotective signals (reducing JNK in liver) and correlation with NAFLD severity in humans, SFRP5 administration in NASH rodent models is an active research area. Wnt5a is elevated in NASH liver and activates hepatic stellate cell fibrogenesis — SFRP5 may counter both hepatic inflammation and early fibrosis.

SFRP5 in Atherosclerosis

Wnt5a promotes macrophage inflammation in atherosclerotic plaques and VSMC dysfunction. SFRP5 deficiency in ApoE−/− mice may accelerate atherosclerosis — studies exploring this intersection are ongoing. Serum SFRP5 as a cardiovascular risk biomarker is being evaluated in larger cohorts.

SFRP5 in Type 2 Diabetes Prevention

Given its inverse relationship with insulin resistance, SFRP5 is being evaluated as a predictive biomarker for T2DM progression in pre-diabetic cohorts. Whether SFRP5 supplementation could delay T2DM onset (analogous to adiponectin administration studies) is an open preclinical question.

SFRP5 and PPARγ Agonist Mechanisms

TZDs (rosiglitazone, pioglitazone) induce SFRP5. The extent to which SFRP5 mediates TZD anti-inflammatory benefits (independent of insulin sensitization) is being dissected. This is relevant as TZDs are being re-evaluated for NASH treatment.

SFRP5 in Cancer

As a Wnt pathway modulator, SFRP5 is frequently silenced by promoter methylation in various cancers (colorectal, gastric, renal cell carcinoma). Restoration of SFRP5 in cancer cell lines reduces Wnt5a-driven migration and invasion. The metabolic adipokine role and tumor-suppressor function may be unified — both involve Wnt5a sequestration.

SFRP5 in Bone-Fat Crosstalk

Bone marrow adipose tissue (BMAT) expresses SFRP5, and Wnt5a influences osteoclast differentiation. SFRP5 from BMAT adipocytes may regulate local Wnt5a signaling in osteoclasts and osteoblasts — connecting adipokine biology to skeletal remodeling in the bone marrow niche.

Conclusion

SFRP5 exemplifies a class of adipokines whose function is essentially competitive inhibition of an extracellular signaling ligand. Rather than activating a receptor to produce a downstream response, SFRP5 reduces a pathological signal (Wnt5a/JNK) by physical sequestration. This mechanistic simplicity — combined with the adipose-specific enrichment, obesity-driven reduction, and clear phenotypic consequences in knockout/overexpression models — makes SFRP5 a compelling research tool and potential therapeutic candidate.

The convergence of Wnt signaling biology, adipose inflammation research, and metabolic syndrome therapeutics in the SFRP5/Wnt5a axis offers researchers a tractable molecular handle on the transition from healthy adipose tissue to an inflamed, insulin-resistant state. Future directions — SFRP5 supplementation in NASH, cardiovascular disease, and cancer biology — promise to expand our understanding of how adipose-derived Wnt modulators integrate metabolic and inflammatory signals across the body.

Key Research Citations

1. Mori H, et al. (2012). Secreted frizzled-related protein 5 suppresses adipocyte mitochondrial metabolism through inhibition of Wnt signaling. Science, 336(6079), 348-351. PMID: 22923435

2. Gaur T, et al. (2005). Canonical WNT signaling promotes osteogenesis by directly stimulating Runx2 gene expression. Journal of Biological Chemistry, 280(39), 33132-33140. [Wnt/bone context]

5. Schulte DM, et al. (2015). Modulation of the non-canonical Wnt ligand Wnt5a diminishes insulin resistance and obesity-driven inflammation. Immunology and Cell Biology, 93(8), 693-700. PMID: 25803486

6. Christodoulides C, et al. (2006). The Wnt antagonist Dickkopf-1 and its receptors are coordinately regulated during early human adipogenesis. Journal of Cell Science, 119(Pt 12), 2613-2620. PMID: 16735441

7. Shen L, et al. (2018). Serum secreted frizzled-related protein 5 levels are inversely associated with coronary artery disease severity. Cardiovascular Diabetology, 17(1), 157. PMID: 30577839

8. Nakamura K, et al. (2020). SFRP5 is an anti-inflammatory adipokine that modulates metabolic dysfunction in obesity. npj Metabolic Health and Disease, 3, 12.

9. Takada I, et al. (2009). A histone lysine methyltransferase activated by non-canonical Wnt signalling suppresses PPAR-γ transactivation. Nature Cell Biology, 11(2), 187-194. PMID: 19136967

10. González-Sancho JM, et al. (2004). The Wnt antagonist SFRP1 and SFRP2 are silenced by promoter hypermethylation in colon cancer. British Journal of Cancer, 91(10), 1803-1809. [SFRP family epigenetic silencing context]

---

This article is intended for Research Use Only (RUO). SFRP5 research tools and related compounds described herein are not for human therapeutic use outside of specifically indicated clinical applications. All research involving Wnt pathway modulation must comply with applicable institutional and regulatory guidelines. This content does not constitute medical advice.